U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489586) titled 'A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration' on March 18.
Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of QL1207H injection versus aflibercept 8 mg in patients with neovascular age-related macular degeneration. The main question it aims to answer is:
* Whether the efficacy and safety of QL1207H and aflibercept 8 mg are similar. Participants will receive injection once every 4 weeks for 3 consecutive doses, followed by injection once every 16 weeks at maximum.
Researchers will compare QL1207H group and aflibercept 8 mg group to s...